Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 11/20 | 0.74 |
| ▸ | HTR2C | P28335 | 8/20 | 0.74 |
| ▸ | HTR2B | P41595 | 7/20 | 0.74 |
| ▸ | HTR6 | P50406 | 2/20 | 0.74 |
| ▸ | HTR1D | P28221 | 2/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | HTR1B | P28222 | 1/20 | 0.74 |
| ▸ | HTR1E | P28566 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.74 |
| ▸ | HTR7 | P34969 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | HTR5A | P47898 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633068 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL22027186 | 0.93 | HTR1A (0.87) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL29403583 | 0.93 | HTR1A (0.87) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL25008692 | 0.91 | HTR1A (0.82) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20970980 | 0.90 | HTR1A (0.82) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL29633120 | 0.90 | HTR1A (0.82) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL25279852 | 0.90 | HTR1A (0.81) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL31105724 | 0.88 | HTR1A (0.79) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL31244448 | 0.88 | HTR1A (0.79) | HTR1AHTR2AHTR2CHTR2BHTR6 | |
| SCHEMBL20970952 | 0.87 | HTR1A (0.78) | HTR1AHTR2AHTR2CHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| CN-120142509-A | Metabolite identified by tryptamine new psychoactive substance 4-HO-DET in zebra fish and application thereof | 浙江警察学院 | 2025-06-13 | — | — | CN | claimed |
| US-20250064783-A1 | Compositions of Matter and Pharmaceutical Compositions | PSILERA INC. | 2025-02-27 | — | — | US | claimed |
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398751-A1 | Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| US-20240325342-A1 | Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023177294-A1 | TRANSMUCOSAL DELIVERY OF PSYCHOACTIVE COMPOUNDS | PLETHORA THERAPEUTICS B.V. (NL) | 2023-09-21 | — | — | WO | claimed |
| EP-4146198-A1 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | Psilera Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| WO-2022248635-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. | OCTARINE BIO APS (DK) | 2022-12-01 | — | — | WO | claimed |
| WO-2022221942-A1 | PREVENTION OF DRUG DIVERSION | BETTERLIFE PHARMA INC. (CA) | 2022-10-27 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| US-20220304980-A1 | METERED DOSING COMPOSITIONS AND METHODS OF USE OF PSYCHEDELIC COMPOUNDS | MARLEY GREEN, LLC | 2022-09-29 | — | — | US | claimed |
| WO-2022082058-A1 | METHOD OF TREATMENT BY TRYPTAMINE ALKALOIDS | ELEUSIS THERAPEUTICS US, INC. (US) | 2022-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | HTR1A 4/4885HTR2A 1/4885HTR2C 2/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR1A 9/4885HTR2A 14/4885HTR2C 42/4885 |
| US-20250064783-A1 | Compositions of Matter and Pharmaceutical Compositions | TPH1, HTR1B, HTR2C | HTR1A 8/4885HTR2A 7/4885HTR2C 3/4885 |
| US-20220304980-A1 | METERED DOSING COMPOSITIONS AND METHODS OF USE OF PSYCHEDELIC COMPOUNDS | PNMT, CRH, HTR5A | HTR1A 5/4885HTR2A 15/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.